Telix Pharmaceuticals Limited (ASX: TLX) it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly’s Olaratumab antibody for the diagnosis and treatment of human cancers.
Telix’s initial development focus will be on a rare type of cancer known as soft tissue sarcoma (STS).
Olaratumab was originally developed by Lilly as a (non-radiolabelled) monoclonal antibody targeting Platelet Derived Growth Factor Receptor Alpha (PDGFRα). PDGFRα is expressed in multiple tumour types including STS.
STS is generally a radiation susceptible cancer that may be inherently amenable to systemic radionuclide therapy and Olaratumab’s ability to target PDGFRα makes it a highly novel and potentially exciting candidate for use as a radionuclide targeting agent.
The exclusive worldwide licence will allow Telix to repurpose Olaratumab as a targeting agent for radiopharmaceutical imaging and therapy of cancer. Olaratumab has an established safety profile that underpins its potential use as a radionuclide targeting agent.
Material terms of the agreement Under the terms of the agreement Telix will pay Lilly an upfront payment of US$5M (~AU$6.7M) for the grant of an exclusive licence to Lilly’s intellectual property related to the development of a radiolabelled Olaratumab, as well as access to material for use by Telix in initial pre-clinical and early phase clinical studies in application to potential uses for the diagnosis and treatment of human cancers.
Lilly may be eligible for up to US$225M (~AU$301M) in payments based upon the achievement of pre-specified development, regulatory and commercial milestones. Lilly would also be eligible to receive industry standard royalties on net sales.
The agreement also includes an option for Lilly to be granted an exclusive licence to a radiolabelled companion diagnostic which would be developed by Telix. If exercised, Lilly will pay Telix US$5M (~AU$6.7M) and up to US$30M (~AU$40.1M) in potential development milestones, as well as industry standard royalties.
Telix Group CEO and Managing Director, Dr. Christian Behrenbruch said this in-licence transaction with Lilly is a valuable – and rare – opportunity to acquire an asset which has demonstrated clinical safety.
“In our pre-transaction diligence and research, we have identified that a radiolabelled version of Olaratumab could be efficacious in patients with STS, particularly as it is a highly radiation-sensitive cancer.
“The safety data generated by Lilly in relation to the original development program significantly de-risks the program for Telix.
“We anticipate that early clinical translation with a radio-labelled Olaratumab as an imaging agent may also provide valuable clinical information as to whether this asset has potential therapeutic efficacy, demonstrating the advantage of Telix’s ‘theranostic’ approach.
“This acquisition mirrors the approach that Telix has taken in building its existing pipeline by in-licencing or acquiring assets that have already been proven to be safe for use in humans that can be harnessed as novel radiolabelled targeting agents. This partnership also demonstrates the value that Telix can bring as a capable partner with the expertise in radiopharmaceutical development and manufacturing, to help repurpose or expand the use of promising candidates to better target, find and treat cancer.”
About Soft Tissue Sarcoma (STS)
Soft Tissue sarcoma is a complex disease that encompasses a diverse group of relatively rare cancers, with more than 50 histological subtypes. In the United States, it is estimated that 13,040 new cases and 5,150 deaths were caused by STS in 2019, representing 0.75% of overall cancer incidence and 0.84% of overall cancer mortality
In Europe, nearly 23,600 new STS cases rose annually, and the crude incidence rate was 4.7 per 100,000.
Standard treatment for soft tissue sarcoma includes surgery, radiation therapy and/or chemotherapy. For patients with advanced, unresectable, or metastatic disease, treatment typically involves chemotherapy with single agents (e.g., doxorubicin) or anthracycline-based combination regimens. However, the prognosis for these patients remains poor, with treated patients with metastatic disease having a median overall survival of around 12–18 months.
